Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer

Keit, Emily; Coutu, B.G.; Zhen, Weining; Zhang, Chi; Lin, Chi Kang; Bennion, N.R.; Ganti, Apar Kishor; Ernani, Vinicius; Baine, Michael J.

doi:10.21037/atm-20-6710

Cited by 13 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since most of the studies usually lean on surgery and/or chemotherapy as treatment modalities, we focused our attention in the literature on the studies on patients who were subjected to radiotherapy, as our aim is to make a comparison with the results of our study. All series had a retrospective design and included patients with locally advanced NSCLC treated with curative radiotherapy 1,23–28 . The inferences obtained can be listed as follows: First, these indices were often examined individually in published studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

et al. 2021

View full text Add to dashboard Cite

Introduction The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate. Methods Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed. Results A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06–1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29–2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18–2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012). Conclusion NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Third, the studies examined the prognostic effects of indices on OS and PFS. LRRFS was not often added as study endpoint 23,27,28 . These studies yielded different results.…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Inflammation is linked to the progression of COVID-19 disease, systemic inflammation is a hallmark of moderate-tosevere COVID-19 disease [51] , which leads to an excessive inflammatory response of the innate and adaptive immune systems, termed Cytokine Release Syndrome (CRS) [52] . Inflammation is also an important part of the tumor environment and plays an important role in the development and progression of malignant tumors [53] . Cancer patients, as one of the most susceptible populations, are facing severe disadvantages during the COVID-19 epidemic, lung cancer patients, in particular [54] , have been reported to be more susceptible to SARS-Cov-2 infection and they are at higher risk of developing pneumonia and severe complications of COVID-19 on admission [55] .…”

Section: Table 4: Molecular Docking Of Colchicine With Core Target Pr...mentioning

confidence: 99%

Potential Mechanism of Colchicine against COVID-19 and Non-Small Cell Lung Cancer based on Network Pharmacology and Bioinformatics Analysis

Liu¹,

Huang²,

Jia³

et al. 2022

IJPS

View full text Add to dashboard Cite

Colchicine is an alkaloid with antitumor effect isolated from Colchicum autumnale plants, it has been reported in multiple studies as a potential treatment for coronavirus disease-19 and this study applied network pharmacology and bioinformatics analysis to explore the potential mechanism of colchicine against non-small cell lung cancer and coronavirus disease-19. The R software was used to determine the differentially expressed genes of non-small cell lung cancer/coronavirus disease-19, and carry out prognostic analysis and clinical analysis of the differentially expressed genes, the targets of colchicine were obtained from various databases, the protein-protein interaction network of intersection targets of colchicine and non-small cell lung cancer/coronavirus disease-19 was constructed, enrichment analysis of gene ontology and kyoto encyclopedia of genes and genomes pathways was performed by Metascape database and the molecular docking and molecular dynamics simulation were completed. We obtained a total of 716 differentially expressed genes and identified 13 potential prognostic genes associated with the clinical characterization of non-small cell lung cancer/coronavirus disease-19 patients. C-C motif chemokine ligand 2, toll like receptor 4, intercellular adhesion molecule 1, peroxisome proliferator activated receptor gamma, interleukin 17A, interferon gamma, angiotensin I converting enzyme, fos proto-oncogene, nuclear factor kappa B inhibitor alpha, TIMP metallopeptidase inhibitor 1 and secreted phosphoprotein 1 were core targets. The intersection targets of colchicine and non-small cell lung cancer/coronavirus disease-19 were mainly enriched in biological processes such as inflammatory response, response to cytokine and response to lipopolysaccharide, as well as signal pathways such as interleukin 17 signaling pathway, hypoxia inducible factor 1 signaling pathway and nucleotide binding oligomerization domain-like receptor signaling pathway. The results of molecular docking showed that the colchicine is better combined with the core targets. Analysis of molecular dynamics simulation showed that the protein and ligand form a stabilizing effect. Based on bioinformatics analysis and network pharmacology, we obtained biomarkers that may be used for the prognosis of non-small cell lung cancer/coronavirus disease-19 patients and revealed that colchicine may play a potential role in the treatment of non-small cell lung cancer/coronavirus disease-19 by regulating multiple targets and multiple signaling pathways and participating in multiple biological processes.

show abstract

“…Katayama et al ( 25 ) found that in bladder cancer, preoperative SII can identify non-muscle invasive bladder cancer patients who have worse disease and prognosis. Keit et al ( 26 ) also found that high SII was associated with low disease control and survival rate of stage III non-small cell lung cancer. However, whether it is associated with recurrent metastasis in GIST has not been reported in a large sample of studies.…”

Section: Introductionmentioning

confidence: 95%

Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors

Cao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundRecent studies have shown that the systemic inflammation and nutritional indicators are prognostic for a variety of malignancies. However, only limited data have so far demonstrated their usefulness in gastrointestinal mesenchymal tumors (GIST).MethodsWe retrospectively analyzed the data of GIST patients who underwent radical surgery in Beijing hospital from October 2004 to July 2018. The area under the receiver operating characteristic curve (AUC) was used to compare several commonly used inflammatory and nutritional indicators. The indicators with largest AUC were further analysis. Optimal cut-off values of those indicators in predicting recurrence-free survival (RFS) were determined. Kaplan-Meier curve and the time-dependent receiver operating characteristic (ROC) curve were used to assess the prognostic values. We then used univariate and multivariate Cox regression analyses to identify prognostic factors that were associated with RFS.ResultsIn total, 160 patients who underwent surgery for GIST were included in the study. The median survival time was 34.5 months, with 1-, 3-, and 5-year RFS rates of 96.1%, 84.7%, and 80.8%, respectively. The inflammatory and nutritional indicators with largest AUC were Systemic immunoinflammatory Index (SII) and Geriatric Nutrition Risk Index (GNRI), reached 0.650 and 0.713, respectively. The optimal cutoff of GNRI and SII were 98.3, and 820.0, respectively. Univariate analysis showed that GNRI, SII, KI67, surgery method, tumor location, tumor size, and mitotic index were all significant prognostic indicators of RFS. After multivariate Cox analysis, independent prognostic factors for RFS in GIST included tumor location, mitotic index, tumor size, and GNRI (HR=2.802,95% CI: 1.045 to 7.515, p = 0.041). Besides, SII also tended to be associated with RFS (HR = 2.970, 95% CI: 0.946 to 9.326, p = 0.062).ConclusionsHigh GNRI is an independent prognostic factor for RFS in GIST, while SII can be considered as a prognostic factor. GNRI and SII can be used as tools to evaluate the prognosis of patients before surgery, helping doctors to better treat high-risk patients.

show abstract

Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer

Cited by 13 publications

References 33 publications

Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

Potential Mechanism of Colchicine against COVID-19 and Non-Small Cell Lung Cancer based on Network Pharmacology and Bioinformatics Analysis

Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors

Contact Info

Product

Resources

About